Curing Gastric Cancer: A New Approach
Author Information
Author(s): A Webb, D Cunningham
Primary Institution: The Royal Marsden Hospital and The Institute of Cancer Research
Hypothesis
Can adjuvant chemotherapy improve survival rates in gastric cancer patients?
Conclusion
Adjuvant chemotherapy may improve outcomes for gastric cancer patients, but it is not yet standard treatment.
Supporting Evidence
- Only about 20% of gastric cancer patients present with surgically curable disease.
- 5-year survival rates for stage I, II, and III gastric cancer are 72%, 32%, and 10%, respectively.
- Adjuvant chemotherapy has shown a significant improvement in 3-year survival for certain treatments.
Takeaway
Doctors are trying new medicines to help people with stomach cancer live longer after surgery. Some treatments are showing promise, but more research is needed.
Methodology
The study involved a prospective randomized trial comparing chemotherapy with surgery alone in node-positive gastric cancer patients.
Limitations
The study is relatively small and may not provide definitive evidence of survival benefits.
Participant Demographics
Patients with node-positive gastric cancer.
Statistical Information
P-Value
0.0009
Confidence Interval
95% confidence interval 0.68-0.98
Statistical Significance
p=0.0009
Want to read the original?
Access the complete publication on the publisher's website